697739-04-1

Basic information

• Product Name: Methyl 3-aMino-5-fluoro-2-Methylbenzoate
• Synonyms: Methyl 3-aMino-5-fluoro-2-Methylbenzoate
• CAS NO: 697739-04-1
• Molecular Weight: 183.182
• Mol File: 697739-04-1.mol

Chemical Properties

• CAS DataBase Reference: Methyl 3-aMino-5-fluoro-2-Methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-aMino-5-fluoro-2-Methylbenzoate(697739-04-1)
• EPA Substance Registry System: Methyl 3-aMino-5-fluoro-2-Methylbenzoate(697739-04-1)

Safety Data

• Hazardous Substances Data: 697739-04-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
Methyl 3-amino-5-fluoro-2-methylbenzoate is utilized as a key building block in the synthesis of a wide range of drugs and drug candidates. Its unique structural features and reactivity make it a valuable component in the development of new pharmaceuticals with improved efficacy and safety profiles.
Used in Medicinal Chemistry Studies:
Methyl 3-aMino-5-fluoro-2-Methylbenzoate is employed as an important target in medicinal chemistry for exploring its potential biological activity and therapeutic applications. Researchers investigate its interactions with biological targets to understand its mechanism of action and optimize its properties for specific medical uses.
Used in Organic Synthesis:
Methyl 3-amino-5-fluoro-2-methylbenzoate's unique structural features and reactivity also make it a valuable tool in organic synthesis. It can be used to explore new pathways and reactions, contributing to the advancement of synthetic organic chemistry and the discovery of novel chemical compounds with potential applications in various fields.

Upstream product

• 850462-64-5 5-fluoro-2-methyl-3-nitrobenzoic acid 
• 33184-16-6 5-fluoro-2-methylbenzoic acid 
• 697739-03-0 5-fluoro-2-methyl-3-nitrobenzoic acid methyl ester 

Downstream Products

• 697739-05-2 methyl 6-fluoro-1H-indazole-4-carboxylate 
• 1403595-36-7 methyl 3-{[(2R,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl](ethyl)amino}-5-fluoro-2-methylbenzoate 
• 1403595-37-8 3-{[(2R,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl](ethyl)amino}-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-fluoro-2-methylbenzamide 
• 1403597-84-1 C₂₄H₃₀FN₂O₂^(1-)*Na⁽¹⁺⁾ 
• 1403595-35-6 methyl 3-{[(2R,6R)-1-benzyl-2,6-dimethylpiperidin-4-yl]amino}-5-fluoro-2-methylbenzoate 

Relevant articles and documents

(AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.

Isoindoline compound, and preparation method, pharmaceutical composition and application thereof

The invention relates to a polysubstituted isoindoline compound represented by a general formula (I), and a preparation method, a pharmaceutical composition and an application thereof. Specifically, as a CRL4CRBNE3 ubiquitin ligase regulator with a novel structure, the polysubstituted isoindoline compound provided by the invention has stronger anti-tumor activity and an anti-tumor spectrum, and can be used for preparing medicines for treating diseases related to CRL4CRBNE3 ubiquitin ligase.

1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containi

ETHER COMPOUNDS AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis and/or cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions of these compounds are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions are also provided.

NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.

Isoindoline derivative and intermediate, preparation method, pharmaceutical composition and application thereof

The invention discloses an isoindoline derivative, and an intermediate, a preparation method, a pharmaceutical composition and application thereof. The isoindoline derivative of the invention and the pharmaceutical composition thereof can adjust productio

TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group opt

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.